Pioglitazone vs Pioglitazone (JT-001)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: PPAR-gamma · full Type 2 Diabetes pipeline
Pioglitazone · Actos
Marketed by Takeda Pharmaceutical Company
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT06989723 (registry estimate)
No aligned efficacy figure on record for this race.
Pioglitazone (JT-001)
Developed by Jeil Pharmaceutical
NCT05101135 · Phase 3 · status unknown
This randomized, double-blind, placebo-controlled trial enrolled 256 patients and measured change in HbA1c, a standard diabetes efficacy measure, at 24 weeks. JT-001 significantly reduced HbA1c versus placebo (p<0.0001), and more patients on JT-001 reached HbA1c targets of below 7% and 6.5%.
ClinicalTrials.gov still shows the planned enrollment of 256; the published report gives 262 randomized (131 per arm).
Reported efficacy
Changes in HbA1c (24th Week): JT-001 (pioglitazone 15mg) add-on vs placebo, week 24 HbA1c change: -0.47% (95% CI -0.61 to -0.33), P<0.0001. HbA1c<7% achieved: 56.8% vs 28%; HbA1c<6.5%: 23.2% vs 9.6% (P<0.0001 for all). (met)
Result source: NCT05101135
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Pioglitazone | Pioglitazone (JT-001) |
|---|---|---|
| HbA1c, change | -1.0% vs -0.3%−0.8 vs placeboNCT01106690102 other results
| —Not reported |
| Body weight, change (kg) | 1.1 vs 1.0+0.1 vs placeboNCT0028649421 other results
| —Not reported |
| HbA1c below 7% | 33% vs 17.5%+15.5 vs placeboNCT010956664 other results
| —Not reported |
| Fasting plasma glucose, change | -1.8 vs 0.1−2 vs placeboNCT01106690105 other results
| —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT00189774 | —Not reported |
HbA1c, change
- Pioglitazone
- -1.0% vs -0.3%−0.8 vs placeboNCT01106690
102 other results
- -0.9% vs -0.3% NCT01106690
- -0.8% vs -0.1% NCT00086502
- -0.8% vs -0.2% NCT00286494
- -0.7% vs -0.2% NCT00286494
- -0.8% vs -0.2% NCT01095666
- -0.8% vs -0.2% NCT01095666
- -1.1% vs -0.6% NCT00641043
- -0.9% vs -0.4% NCT01289119
- -0.3% vs -0.4% NCT01289119
- -0.8% vs -0.4% NCT01289119
- -0.4% vs 0.4% NCT00372060
- -1.2% vs -0.9% NCT00722371
- -0.9% vs -0.4% NCT01183013
- -1.2% vs -1.1% NCT00722371
- -1.4% vs -0.9% NCT00722371
- -1.5% vs -0.9% NCT00722371
- -1.8% vs -0.9% NCT00722371
- -2.4% vs -1.9% NCT01028391
- -1.5% vs -1.1% NCT00722371
- -1.6% vs -1.1% NCT00722371
- -1.8% vs -1.1% NCT00722371
- -2.4% vs -1.5% NCT00397631
- -1.2% vs -0.9% NCT00722371
- -0.7% vs -0.4% NCT01183013
- -1.2% vs -1.1% NCT00722371
- -0.7% vs -0.3% NCT00432276
- -0.9% vs -0.4% NCT00432276
- -1.0% vs -0.2% NCT01318070
- -0.7% vs -0.9% NCT00722371
- -0.7% vs -0.4% NCT01183013
- -0.9% vs -1.1% NCT00722371
- -0.9% vs -0.2% NCT01318070
- -0.8% vs -0.4% NCT01183013
- -1.1% vs -0.4% NCT01183013
- -1.3% vs -0.4% NCT01183013
- -0.8% vs -0.3% NCT00286494
- -0.8% vs -0.3% NCT00286494
- -0.8% vs -0.2% NCT00286494
- -0.7% vs -0.2% NCT00286494
- -0.5% vs -0.1% NCT00286494
- -0.7% vs -0.3% NCT00286494
- -0.7% vs -0.3% NCT00286494
- -0.7% vs -0.2% NCT00286494
- -0.6% vs -0.2% NCT00286494
- -0.4% vs -0.1% NCT00286494
- -1.1% vs -0.6% NCT00641043
- -0.9% vs -0.4% NCT01289119
- -0.8% vs -0.3% NCT00641043
- -0.4% vs -0.0% NCT00641043
- -0.6% vs -0.9% NCT00372060
- -0.3% vs -0.4% NCT01289119
- -0.8% vs -0.4% NCT01289119
- -0.7% vs -0.4% NCT01289119
- -0.3% vs -0.4% NCT01289119
- -0.7% vs -0.4% NCT01289119
- -0.4% vs -0.2% NCT01289119
- -0.1% vs -0.2% NCT01289119
- -0.4% vs -0.2% NCT01289119
- -0.9% vs -0.4% NCT01183013
- -0.9% vs -0.4% NCT01183013
- -0.8% vs -0.4% NCT01183013
- -0.6% vs -0.4% NCT01183013
- -0.2% vs -0.2% NCT01183013
- -0.7% vs -0.4% NCT01183013
- -0.7% vs -0.4% NCT01183013
- -0.6% vs -0.4% NCT01183013
- -0.4% vs -0.4% NCT01183013
- -0.2% vs -0.2% NCT01183013
- -0.8% vs -0.4% NCT00432276
- -0.8% vs -0.4% NCT00432276
- -0.9% vs -0.5% NCT00432276
- -0.9% vs -0.4% NCT00432276
- -0.8% vs -0.3% NCT00432276
- -0.7% vs -0.3% NCT00432276
- -0.8% vs -0.2% NCT01318070
- -0.4% vs -0.1% NCT00432276
- -0.5% vs -0.1% NCT01318070
- -0.2% vs -0.0% NCT01318070
- -0.8% vs -0.4% NCT01183013
- -0.8% vs -0.4% NCT01183013
- -0.6% vs -0.4% NCT01183013
- -0.5% vs -0.4% NCT01183013
- -0.2% vs -0.2% NCT01183013
- -0.8% vs -0.2% NCT01318070
- -0.5% vs -0.1% NCT01318070
- -0.2% vs -0.0% NCT01318070
- -0.9% vs -0.4% NCT01183013
- -1.1% vs -0.4% NCT01183013
- -1.3% vs -0.4% NCT01183013
- -0.8% vs -0.4% NCT01183013
- -1.1% vs -0.4% NCT01183013
- -1.2% vs -0.4% NCT01183013
- -0.8% vs -0.4% NCT01183013
- -1.1% vs -0.4% NCT01183013
- -1.2% vs -0.4% NCT01183013
- -0.7% vs -0.4% NCT01183013
- -0.9% vs -0.4% NCT01183013
- -1.0% vs -0.4% NCT01183013
- -0.4% vs -0.2% NCT01183013
- -0.5% vs -0.2% NCT01183013
- -0.6% vs -0.2% NCT01183013
- -0.3% vs 0.2% NCT00443755
- Pioglitazone (JT-001)
- —Not reported
Body weight, change (kg)
- Pioglitazone
- 1.1 vs 1.0+0.1 vs placeboNCT00286494
21 other results
- 0.9 vs 0.9 NCT00286494
- 0.6 vs 0.6 NCT00286494
- 0.4 vs 0.4 NCT00286494
- 1.5 vs 1.0 NCT00286494
- 1.1 vs 0.9 NCT00286494
- 0.7 vs 0.6 NCT00286494
- 0.5 vs 0.4 NCT00286494
- -2.6 vs -0.7 NCT01095666
- -1.8 vs -0.7 NCT01095666
- -0.8 vs -1.6 NCT01289119
- -0.7 vs -1.6 NCT01289119
- -0.1 vs -1.6 NCT01289119
- -0.4 vs -1.0 NCT01289119
- -0.7 vs -1.0 NCT01289119
- -0.1 vs -1.0 NCT01289119
- 1.1 vs 1.6 NCT00432276
- 1.1 vs 1.5 NCT00432276
- 0.7 vs 1.0 NCT00432276
- 0.3 vs 0.6 NCT00432276
- 0.3 vs 0.5 NCT00432276
- 0.2 vs 0.3 NCT00432276
- Pioglitazone (JT-001)
- —Not reported
HbA1c below 7%
- Pioglitazone
- 33% vs 17.5%+15.5 vs placeboNCT01095666
4 other results
- 32.9% vs 17.5% NCT01095666
- 55.1% vs 30% NCT01289119
- 31.7% vs 30% NCT01289119
- 61.7% vs 30% NCT01289119
- Pioglitazone (JT-001)
- —Not reported
Fasting plasma glucose, change
- Pioglitazone
- -1.8 vs 0.1−2 vs placeboNCT01106690
105 other results
- -1.5 vs 0.1 NCT01106690
- -0.9 vs 0.1 NCT00086502
- -1.1 vs -0.3 NCT00286494
- -1.2 vs -0.4 NCT00286494
- -1.3 vs -0.5 NCT00286494
- -1.4 vs -0.6 NCT00286494
- -1.5 vs -0.3 NCT00286494
- -1.4 vs -0.2 NCT00286494
- -1.2 vs -0.1 NCT00286494
- -1.0 vs -0.1 NCT00286494
- -1.1 vs -0.3 NCT00286494
- -1.2 vs -0.4 NCT00286494
- -1.0 vs -0.5 NCT00286494
- -1.1 vs -0.6 NCT00286494
- -1.3 vs -0.3 NCT00286494
- -1.3 vs -0.2 NCT00286494
- -1.2 vs -0.1 NCT00286494
- -0.8 vs -0.1 NCT00286494
- -1.5 vs 0.0 NCT01095666
- -1.2 vs 0.0 NCT01095666
- -1.8 vs -1.0 NCT00641043
- -1.8 vs -1.1 NCT00641043
- -1.2 vs -0.3 NCT01289119
- -1.9 vs -1.1 NCT00641043
- -1.9 vs -0.9 NCT00641043
- -0.1 vs -0.3 NCT01289119
- -1.1 vs -0.3 NCT01289119
- -1.3 vs -0.4 NCT01289119
- -0.2 vs -0.4 NCT01289119
- -1.2 vs -0.4 NCT01289119
- -0.7 vs 0.2 NCT00372060
- -1.3 vs -0.3 NCT01289119
- -0.0 vs -0.3 NCT01289119
- -0.9 vs -0.3 NCT01289119
- -1.0 vs -0.3 NCT01289119
- 0.3 vs -0.3 NCT01289119
- -1.0 vs -0.3 NCT01289119
- -1.9 vs -0.7 NCT00722371
- -1.6 vs -0.1 NCT01183013
- -1.8 vs 0 NCT01183013
- -1.5 vs -0.3 NCT01183013
- -2.1 vs -1.4 NCT00722371
- -1.6 vs -0.4 NCT01183013
- -1.4 vs -0.4 NCT01183013
- -0.9 vs -0.2 NCT01183013
- -1.9 vs -0.7 NCT00722371
- -2.1 vs -0.7 NCT00722371
- -2.6 vs -0.7 NCT00722371
- -3.4 vs -2.9 NCT01028391
- -2.3 vs -1.4 NCT00722371
- -2.6 vs -1.4 NCT00722371
- -2.9 vs -1.4 NCT00722371
- -3.5 vs -2.2 NCT00397631
- -1.3 vs -0.7 NCT00722371
- -1.4 vs -0.1 NCT01183013
- -1.4 vs 0 NCT01183013
- -1.2 vs -0.3 NCT01183013
- -1.7 vs -1.4 NCT00722371
- -0.8 vs -0.2 NCT00432276
- -0.9 vs -0.3 NCT00432276
- -0.8 vs -0.3 NCT00432276
- -0.9 vs -0.3 NCT00432276
- -0.9 vs -0.3 NCT00432276
- -1 vs -0.3 NCT00432276
- -1.1 vs -0.3 NCT00432276
- -1.1 vs -0.3 NCT00432276
- -1.0 vs -0.1 NCT00432276
- -0.9 vs -0.0 NCT00432276
- -1.1 vs -0.4 NCT01183013
- -1.2 vs -0.4 NCT01183013
- -0.9 vs -0.2 NCT01183013
- -1.1 vs -0.1 NCT01318070
- -1.2 vs -0.2 NCT01318070
- -1.0 vs -0.2 NCT01318070
- -0.9 vs -0.2 NCT01318070
- -0.6 vs -0.7 NCT00722371
- -0.8 vs -0.1 NCT01183013
- -1.0 vs 0 NCT01183013
- -0.9 vs -0.3 NCT01183013
- -1.1 vs -1.4 NCT00722371
- -0.9 vs -0.4 NCT01183013
- -0.6 vs -0.4 NCT01183013
- -0.8 vs -0.2 NCT01183013
- -0.8 vs -0.1 NCT01318070
- -0.9 vs -0.2 NCT01318070
- -0.8 vs -0.2 NCT01318070
- -0.7 vs -0.2 NCT01318070
- -1.1 vs -0.1 NCT01183013
- -1.5 vs -0.1 NCT01183013
- -1.9 vs -0.1 NCT01183013
- -1 vs 0 NCT01183013
- -1.5 vs 0 NCT01183013
- -1.9 vs 0 NCT01183013
- -0.9 vs -0.3 NCT01183013
- -1.8 vs -0.3 NCT01183013
- -1.8 vs -0.3 NCT01183013
- -1.1 vs -0.4 NCT01183013
- -1.7 vs -0.4 NCT01183013
- -1.7 vs -0.4 NCT01183013
- -1 vs -0.4 NCT01183013
- -1.7 vs -0.4 NCT01183013
- -1.6 vs -0.4 NCT01183013
- -1.1 vs -0.2 NCT01183013
- -1.5 vs -0.2 NCT01183013
- -1.6 vs -0.2 NCT01183013
- Pioglitazone (JT-001)
- —Not reported
3-point MACE (% with event)
- Pioglitazone
- —Not posted · NCT00189774
- Pioglitazone (JT-001)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Pioglitazone: 4 of 4 rows · Pioglitazone (JT-001): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Pioglitazone |
|---|---|
| Dropout rate | 34.4%a NCT01107717 · Phase 4 · registry result, not featured evidence · combination show 41 more results50%30 mg NCT01972724 · Phase 4 · registry result, not featured evidence —30 mg NCT01972724 · Phase 4 · registry result, not featured evidence 47.4%15 mg NCT01972724 · Phase 4 · registry result, not featured evidence 4.6%10 mg NCT01095666 · Phase 3 · registry result, not featured evidence · combination 7.5%5 mg NCT01095666 · Phase 3 · registry result, not featured evidence · combination 29.7%45 mg NCT01183013 · Phase 3 · registry result, not featured evidence 27.9%30 mg NCT01183013 · Phase 3 · registry result, not featured evidence 34.4%15 mg / 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence 28.6%5 mg + 15 mg / 5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 33.8%5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 27.8%5 mg + 45 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 11.4%300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence 8%100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence 6.1%Metformin + Alogliptin Add-on Ther NCT01289119 · Phase 3 · registry result, not featured evidence · combination 7.9%Pioglitazone NCT01289119 · Phase 3 · registry result, not featured evidence 6.6%Pioglitazone + Alogliptin Add-on T NCT01289119 · Phase 3 · registry result, not featured evidence · combination 27.4%45 mg NCT00722371 · Phase 3 · registry result, not featured evidence 20.9%100 mg/15 mg NCT00722371 · Phase 3 · registry result, not featured evidence · combination 22.9%100 mg/30 mg NCT00722371 · Phase 3 · registry result, not featured evidence · combination 22.2%100 mg/45 mg NCT00722371 · Phase 3 · registry result, not featured evidence · combination 27.9%30 mg NCT00722371 · Phase 3 · registry result, not featured evidence 31.3%15 mg NCT00722371 · Phase 3 · registry result, not featured evidence 30%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin NCT00432276 · Phase 3 · registry result, not featured evidence · combination 5.8% NCT00641043 · Phase 3 · registry result, not featured evidence · combination 20.6%15 mg and Metformin 850 mg BID NCT00770653 · Phase 3 · registry result, not featured evidence · combination 8.5%100 mg q.d. + 45 mg q.d. NCT01028391 · Phase 3 · registry result, not featured evidence · combination 11.5%100 mg q.d. + 30 mg q.d. NCT00397631 · Phase 3 · registry result, not featured evidence · combination 4.5%Sitagliptin / Sitagliptin NCT00372060 · Phase 3 · registry result, not featured evidence —Sitagliptin/Sitagliptin (Data Thro NCT00372060 · Phase 3 · registry result, not featured evidence 19.6%25 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 22.3%12.5 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 14.9%100 mg NCT00086502 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 1.8%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 1.8%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 14.3% NCT00443755 · Phase 2 · registry result, not featured evidence 9.6%100 mg + 30 mg NCT00511108 · Phase 1 · registry result, not featured evidence · combination 3.7%30 mg NCT00511108 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT01107717 · Phase 4 · registry result, not featured evidence · combination show 41 more results0%30 mg NCT01972724 · Phase 4 · registry result, not featured evidence —30 mg NCT01972724 · Phase 4 · registry result, not featured evidence 5.3%15 mg NCT01972724 · Phase 4 · registry result, not featured evidence 2%10 mg NCT01095666 · Phase 3 · registry result, not featured evidence · combination 0.7%5 mg NCT01095666 · Phase 3 · registry result, not featured evidence · combination 3.6%45 mg NCT01183013 · Phase 3 · registry result, not featured evidence 5.7%30 mg NCT01183013 · Phase 3 · registry result, not featured evidence 4.6%15 mg / 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence 7.9%5 mg + 15 mg / 5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 7.5%5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 4.5%5 mg + 45 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 3.5%300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence 0.9%100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence 2%Metformin + Alogliptin Add-on Ther NCT01289119 · Phase 3 · registry result, not featured evidence · combination 1.6%Pioglitazone NCT01289119 · Phase 3 · registry result, not featured evidence 0%Pioglitazone + Alogliptin Add-on T NCT01289119 · Phase 3 · registry result, not featured evidence · combination 4.3%45 mg NCT00722371 · Phase 3 · registry result, not featured evidence 2.6%100 mg/15 mg NCT00722371 · Phase 3 · registry result, not featured evidence · combination 3.5%100 mg/30 mg NCT00722371 · Phase 3 · registry result, not featured evidence · combination 1.7%100 mg/45 mg NCT00722371 · Phase 3 · registry result, not featured evidence · combination 3.9%30 mg NCT00722371 · Phase 3 · registry result, not featured evidence 5.7%15 mg NCT00722371 · Phase 3 · registry result, not featured evidence 3.2%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin NCT00432276 · Phase 3 · registry result, not featured evidence · combination 1.5% NCT00641043 · Phase 3 · registry result, not featured evidence · combination 8.4%15 mg and Metformin 850 mg BID NCT00770653 · Phase 3 · registry result, not featured evidence · combination 2.4%100 mg q.d. + 45 mg q.d. NCT01028391 · Phase 3 · registry result, not featured evidence · combination 1.9%100 mg q.d. + 30 mg q.d. NCT00397631 · Phase 3 · registry result, not featured evidence · combination 3%Sitagliptin / Sitagliptin NCT00372060 · Phase 3 · registry result, not featured evidence —Sitagliptin/Sitagliptin (Data Thro NCT00372060 · Phase 3 · registry result, not featured evidence 3%25 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 4.1%12.5 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 6.3%100 mg NCT00086502 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 0.9%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 0.9%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination — NCT00443755 · Phase 2 · registry result, not featured evidence 1.9%100 mg + 30 mg NCT00511108 · Phase 1 · registry result, not featured evidence · combination 0%30 mg NCT00511108 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 0%a NCT01107717 · Phase 4 · registry result, not featured evidence · combination show 41 more results0%30 mg NCT01972724 · Phase 4 · registry result, not featured evidence 3.9%30 mg NCT01972724 · Phase 4 · registry result, not featured evidence 5.9%15 mg NCT01972724 · Phase 4 · registry result, not featured evidence 2%10 mg NCT01095666 · Phase 3 · registry result, not featured evidence · combination 2%5 mg NCT01095666 · Phase 3 · registry result, not featured evidence · combination 3.6%45 mg NCT01183013 · Phase 3 · registry result, not featured evidence 6.4%30 mg NCT01183013 · Phase 3 · registry result, not featured evidence 6.9%15 mg / 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence 7.1%5 mg + 15 mg / 5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 11.3%5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 7.5%5 mg + 45 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence 3.5%300 mg NCT01106690 · Phase 3 · registry result, not featured evidence 6.1%300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence 2.7%100 mg NCT01106690 · Phase 3 · registry result, not featured evidence 7.1%100 mg NCT01106690 · Phase 3 · registry result, not featured evidence 0%Metformin + Alogliptin Add-on Ther NCT01289119 · Phase 3 · registry result, not featured evidence · combination 0%Pioglitazone NCT01289119 · Phase 3 · registry result, not featured evidence 1.6%Pioglitazone + Alogliptin Add-on T NCT01289119 · Phase 3 · registry result, not featured evidence · combination 4.8%45 mg NCT00722371 · Phase 3 · registry result, not featured evidence 5.2%100 mg/15 mg NCT00722371 · Phase 3 · registry result, not featured evidence · combination 6.5%100 mg/30 mg NCT00722371 · Phase 3 · registry result, not featured evidence · combination 3%100 mg/45 mg NCT00722371 · Phase 3 · registry result, not featured evidence · combination 2.1%30 mg NCT00722371 · Phase 3 · registry result, not featured evidence 4.3%15 mg NCT00722371 · Phase 3 · registry result, not featured evidence 5%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin NCT00432276 · Phase 3 · registry result, not featured evidence · combination 3.1% NCT00641043 · Phase 3 · registry result, not featured evidence · combination 11.1%15 mg and Metformin 850 mg BID NCT00770653 · Phase 3 · registry result, not featured evidence · combination 3%100 mg q.d. + 45 mg q.d. NCT01028391 · Phase 3 · registry result, not featured evidence · combination —100 mg q.d. + 30 mg q.d. NCT00397631 · Phase 3 · registry result, not featured evidence · combination —Sitagliptin / Sitagliptin NCT00372060 · Phase 3 · registry result, not featured evidence —Sitagliptin/Sitagliptin (Data Thro NCT00372060 · Phase 3 · registry result, not featured evidence 6.5%25 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 2.5%12.5 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 2.9%100 mg NCT00086502 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 1.8%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 0.9%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 0% NCT00443755 · Phase 2 · registry result, not featured evidence 1.9%100 mg + 30 mg NCT00511108 · Phase 1 · registry result, not featured evidence · combination 0%30 mg NCT00511108 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | a nausea 25.2% hypoglycemia 13.6% peripheral edema 4.9% NCT01107717 · Phase 4 · registry result, not featured evidence · combination show 37 more results30 mg oedema 11.8% eyelid oedema 5.9% folliculitis 5.9% NCT01972724 · Phase 4 · registry result, not featured evidence 30 mg conjunctival haemorrhage 0% eyelid oedema 0% folliculitis 0% NCT01972724 · Phase 4 · registry result, not featured evidence 15 mg conjunctival haemorrhage 5.9% ligament injury 5.9% nasopharyngitis 5.9% NCT01972724 · Phase 4 · registry result, not featured evidence 10 mg hyperlipidaemia 11.8% (placebo 11%) urinary tract infection 6.6% (placebo 4.8%) nasopharyngitis 4.6% (placebo 3.4%) NCT01095666 · Phase 3 · registry result, not featured evidence · combination 5 mg hyperlipidaemia 12.2% (placebo 11%) upper respiratory tract infection 9.5% (placebo 2.1%) nasopharyngitis 6.1% (placebo 3.4%) NCT01095666 · Phase 3 · registry result, not featured evidence · combination 45 mg oedema peripheral 8% back pain 7.2% arthralgia 6.5% NCT01183013 · Phase 3 · registry result, not featured evidence 30 mg oedema peripheral 7.9% hyperglycaemia 7.1% nasopharyngitis 7.1% NCT01183013 · Phase 3 · registry result, not featured evidence 15 mg / 30 mg oedema peripheral 9.9% back pain 9.2% hypertension 9.2% NCT01183013 · Phase 3 · registry result, not featured evidence 5 mg + 15 mg / 5 mg + 30 mg diarrhoea 7.9% nasopharyngitis 7.1% back pain 6.3% NCT01183013 · Phase 3 · registry result, not featured evidence · combination 5 mg + 30 mg oedema 9% dizziness 6.8% oedema peripheral 6.8% NCT01183013 · Phase 3 · registry result, not featured evidence · combination 5 mg + 45 mg oedema peripheral 11.3% back pain 9% urinary tract infection 5.3% NCT01183013 · Phase 3 · registry result, not featured evidence · combination 300 mg nasopharyngitis 9.6% (placebo 5.2%) pollakiuria 6.1% (placebo 0.9%) arthralgia 5.3% (placebo 1.7%) NCT01106690 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 13.2% (placebo 5.2%) arthralgia 7.9% (placebo 1.7%) urinary tract infection 7.9% (placebo 5.2%) NCT01106690 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 8% (placebo 6.1%) back pain 7.1% (placebo 2.6%) nasopharyngitis 5.3% (placebo 5.2%) NCT01106690 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 12.4% (placebo 6.1%) nasopharyngitis 9.7% (placebo 5.2%) back pain 8.8% (placebo 2.6%) NCT01106690 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 3% (placebo 3.3%) blood triglycerides increased 2% (placebo 1.1%) urinary tract infection 2% (placebo 6.5%) NCT01289119 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 9.5% (placebo 3.3%) blood triglycerides increased 6.3% (placebo 1.1%) hyperlipidaemia 6.3% (placebo 1.1%) NCT01289119 · Phase 3 · registry result, not featured evidence hyperlipidaemia 21.3% (placebo 1.1%) urinary tract infection 6.6% (placebo 6.5%) upper respiratory tract infection 3.3% (placebo 3.3%) NCT01289119 · Phase 3 · registry result, not featured evidence · combination 45 mg hypoglycaemia 8.7% upper respiratory tract infection 5.2% headache 4.8% NCT00722371 · Phase 3 · registry result, not featured evidence 100 mg/15 mg hypoglycaemia 8.7% hypertension 5.7% nasopharyngitis 5.2% NCT00722371 · Phase 3 · registry result, not featured evidence · combination 100 mg/30 mg hypoglycaemia 11.3% nasopharyngitis 6.5% headache 6.1% NCT00722371 · Phase 3 · registry result, not featured evidence · combination 100 mg/45 mg hypoglycaemia 10.4% upper respiratory tract infection 4.8% nasopharyngitis 3.5% NCT00722371 · Phase 3 · registry result, not featured evidence · combination 30 mg hypoglycaemia 9.4% nasopharyngitis 5.2% headache 3.9% NCT00722371 · Phase 3 · registry result, not featured evidence 15 mg hypoglycaemia 8.7% nasopharyngitis 4.3% headache 2.6% NCT00722371 · Phase 3 · registry result, not featured evidence Alogliptin 25 mg; Pioglitazone 30 mg; Metformin upper respiratory tract infection 7.2% nasopharyngitis 6.9% hypertension 5.9% NCT00432276 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 9.3% (placebo 8.5%) upper respiratory tract infection 3.5% (placebo 7.7%) NCT00641043 · Phase 3 · registry result, not featured evidence · combination 15 mg and Metformin 850 mg BID nasopharyngitis 15.7% diarrhoea 9.2% arthralgia 5.2% NCT00770653 · Phase 3 · registry result, not featured evidence · combination 100 mg q.d. + 45 mg q.d. all infections and infestations 4.9% nasopharyngitis 4.9% NCT01028391 · Phase 3 · registry result, not featured evidence · combination 100 mg q.d. + 30 mg q.d. any nervous system disorders 3.4% headache 3.4% any infections and infestations 3.1% NCT00397631 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 16.7% (placebo 25%) upper respiratory tract inflammation 13.6% (placebo 4.4%) weight increased 3% (placebo 0%) NCT00372060 · Phase 3 · registry result, not featured evidence 25 mg QD nasopharyngitis 7% (placebo 6.2%) influenza 5.5% (placebo 4.1%) oedema peripheral 5.5% (placebo 7.2%) NCT00286494 · Phase 3 · registry result, not featured evidence 12.5 mg QD oedema peripheral 6.1% (placebo 7.2%) upper respiratory tract infection 5.6% (placebo 5.2%) nausea 4.5% (placebo 2.1%) NCT00286494 · Phase 3 · registry result, not featured evidence 100 mg any infections and infestations 6.3% (placebo 3.4%) upper respiratory tract infection 6.3% (placebo 3.4%) any nervous system disorders 5.1% (placebo 3.9%) NCT00086502 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD nasopharyngitis 11.5% blood creatine phosphokinase increased 3.5% dental caries 0% NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD nasopharyngitis 4.5% blood creatine phosphokinase increased 0% dental caries 0% NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 100 mg + 30 mg blood glucose increased 0% (placebo 5.7%) headache 0% (placebo 5.7%) hyperglycaemia 0% (placebo 0%) NCT00511108 · Phase 1 · registry result, not featured evidence · combination 30 mg upper respiratory tract infection 5.6% (placebo 5.7%) blood glucose increased 0% (placebo 5.7%) headache 0% (placebo 5.7%) NCT00511108 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 41 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Pioglitazone
show 2 more results
show 2 more results
show 102 more results
show 105 more results
show 13 more results
show 21 more results
show 4 more results
show 5 more results
show 5 more results
show 7 more results
+ 44 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Pioglitazone's landscape · Pioglitazone (JT-001)'s landscape